Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children

Journal of the American Academy of Dermatology

Volumn 38, Issue 1, 1998, Pages 69-76

  Alaiti, S ^a   Kang, S ^a   Fiedler, V C ^a   Ellis, C N ^a   Spurlin, D V ^a   Fader, D ^a   Ulyanov, G ^a   Gadgil, S D ^a   Tanase, A ^a   Lawrence, I ^a   Scotellaro, P ^a   Raye, K ^a   Bekersky, I ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FLUSHING; HUMAN; MALE; MULTICENTER STUDY; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VASODILATATION;

EID: 18544392044     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(98)70541-9     Document Type: Article

References (19)

1. AR Halbert The practical management of atopic dermatitis in children Pediatr Ann 25 1996 72 77
2. M Boguniewicz DYM Leung New concepts in atopic dermatitis Compr Ther 22 1996 144 151
3. R Graham-Brown Managing adults with atopic dermatitis Dermatol Clin 14 1996 531 537
4. MS Ehlayel Atopic dermatitis: immunopathology and therapeutic implications J Bahrain Med Soc 8 1996 43 51
5. J Bird J Montana New therapeutic approaches to atopic dermatitis Exp Opin Invest Drugs 5 1996 1173 1180
6. AI Lauerma HI Maibach Topical FK506: Clinical potential or laboratory curiosity? Dermatology 188 1994 173 176
7. PA Kelly GJ Burckart R Venkataramanan Tacrolimus: a new immunosuppressive agent Am J Health-Syst Pharm 52 1995 1521 1535
8. PJ Ptachcinski R Venkataramanan GJ Burckart Clinical pharmacokinetics of cyclosporine Clin Pharmacol 11 1986 107 132
9. J Shupack E Abel E Bauer M Brown L Drake R Freinkel Cyclosporine as maintenance therapy in patients with severe psoriasis J Am Acad Dermatol 36 1997 423 432
10. K Abu-Elmagd D Van Thiel BV Jegasothy CD Ackerman S Todo JJ Fung FK506: a new therapeutic agent for severe recalcitrant psoriasis Transplant Proc 23 1991 3322 3324
11. JJ Fung M Alessiani K Abu-Elmagd S Todo R Shapiro A Tzakis Adverse effects associated with the use of FK 506 Transplant Proc 23 1991 3105 3108
12. DA Laskow F Vincenti JF Neylan R Mendez AJ Matas An open-label, concentration-ranging trial of FK506 in primary kidney transplantation Transplantation 62 1996 900 905
13. RP Kershner WE Fitzsimmons Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation Transplantation 62 1996 920 926
14. P McMaster DF Mirza T Ismail G Vennarecci P Patapis AD Mayer Therapeutic drug monitoring of tacrolimus in clinical transplantation Ther Drug Monit 17 1995 602 605
15. H Aoyama N Tabata M Tanaka Y Uesugi H Tagami Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment Br J Dermatol 133 1995 494 496
16. H Nakagawa T Etoh Y Ishibashi Y Higaki M Kawashima H Torii Effects of tacrolimus (FK506) ointment for facial atopic dermatitis Allergy 50 1995 368
17. JM Hanifin G Rajka Diagnostic features of atopic dermatitis Acta Derm Venereol (Stockh) 92 1980 44 47
18. G Rajka T Langeland Grading of the severity of atopic dermatitis Acta Derm Venereol (Stockh) 144 1989 13 14
19. WJ Jusko W Piekoszewski GB Klintmalm MS Shaefer MF Hebert AA Piergies Pharmacokinetics of tacrolimus in liver transplant patients Clin Pharmacol Ther 57 1995 281 290